INDVIndivior Pharmaceuticals, Inc.
Is the price fair?
Cheap vs its sector. That is the only one of 3 checks this filer's data supports, so take it as a single data point rather than a settled answer.
Sector median 22.6× across 130 covered peers. EV/EBIT counts debt as part of the price, so a cash-rich and a borrowed company can be compared on the same footing.
Against the whole market›
Percentile against every name Ryufin tracks. Higher is better; the tick marks the middle of the market. Context, not one of the checks above.
Where this answer is blind. The growth-implied estimate assumes a fixed discount rate; capital-heavy sectors look structurally rich on it.
What INDV's price assumes
Indivior Pharmaceuticals, Inc. trades at 12.8× earnings against 19.7× for the median Drug Manufacturers - Specialty & Generic name, cheaper than its own group.
Trailing P/E · Drug Manufacturers - Specialty & Generic median 19.7 · cheaper than the typical name in its group
- Price / sales
- 3.66
Price / sales · today's price, trailing year to Jun 30, 2026
- EV / sales
- 3.86
EV / sales
Details›
- EV / EBITtoday's price, trailing year to Jun 30, 2026
- 12.2
- EV / salestoday's price, trailing year to Jun 30, 2026
- 3.86
- Healthcare median P/E509 names
- 26.2
- Drug Manufacturers - Specialty & Generic median P/E45 names
- 19.7
- Market capitalisation
- $4.88B
Multiples from SEC filings and end-of-day closes; implied growth from a reverse discounted cash flow. Group medians across the names Ryufin tracks.
Drug Manufacturers, Specialty & Generic
Ranks #1 of 41 by RyuScore